|
시장보고서
상품코드
2078291
환자 유래 이종이식 모델 시장 : 모델 종류별, 이식 방법별, 종양 종류별, 용도별, 최종사용자별, 지역별Patient Derived Xenograft Model Market, By Model Type, By Implantation Method, By Tumor Type, By Application, By End User, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
환자 유래 이종이식 모델 시장은 2026년에 1억 7,500만 달러 규모에 달할 것으로 추정되며, 2033년까지 5억 8,090만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 18.7%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 1억 7,500만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 18.70% | 예측 금액(2033년) | 5억 8,090만 달러 |
전 세계 환자 유래 이종이식 모델 시장은 세포주 유래 모델, 환자 유래 오가노이드, 유전자 조작 모델, 기타(1세대 세포 유래 모델, 세포 처리 모델 등)를 포함한 광범위한 모델 유형을 아우르며, 소화기 종양 모델, 부인과 종양 모델, 호흡기 종양 모델, 기타 종양 모델 등의 용도로 활용되고 있습니다. 수요는 제약·바이오기술 기업 및 CRO(의약품 개발 업무 수탁 기관)의 도입과, 보다 효율적이고 신뢰할 수 있는 솔루션에 대한 요구에 힘입어 증가하고 있습니다. 지속적인 기술 발전과 최종사용자의 요구 증가가 이 시장의 성장을 주도하고 있습니다.
시장 역학:
소화기 종양 모델 및 부인과 종양 모델에서의 채택 확대, 최종사용자의 수요 증가, 그리고 효율성과 성능 향상을 위한 지속적인 노력이 전 세계 환자 유래 이종이식 모델 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 이용 가능한 선택의 폭이 넓어짐에 따라, 더 다양한 사용자층이 이러한 솔루션을 이용할 수 있게 되었습니다.
예를 들어, 각 기업은 제약·바이오기술 기업이나 CRO의 변화하는 요구 사항에 대응하기 위해 제품 포트폴리오를 확대하고 있습니다. 또한, 혁신 및 신기술 통합에 대한 투자 증가로 인해 예측 기간 동안 시장 참여자들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 인사이트도 제공하고 있습니다.
- 전 세계 환자 유래 이종이식 모델 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 수록하고 있습니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계 환자 유래 이종이식 모델 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 환자 유래 이종이식 모델 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 환자 유래 이종이식 모델 시장 : 모델 종류별(2021-2033년)
제5장 환자 유래 이종이식 모델 시장 : 이식 방법별(2021-2033년)
제6장 환자 유래 이종이식 모델 시장 : 종양 종류별(2021-2033년)
제7장 환자 유래 이종이식 모델 시장 : 최종사용자별(2021-2033년)
제8장 환자 유래 이종이식 모델 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 섹션
KSM 26.07.15Patient Derived Xenograft Model Market is estimated to be valued at USD 175.0 Mn in 2026 and is expected to reach USD 580.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 18.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 175.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 18.70% | 2033 Value Projection: | USD 580.9 Mn |
The global patient derived xenograft model market covers a broad set of model type categories, including Cell line derived models, Patient derived organoids, and Genetically engineered models and Others (Primary cell derived models, cell processed models etc.), used across applications such as Gastrointestinal Tumor Model, Gynecological Tumor Model, and Respiratory Tumor Model and Other Tumor Model. Demand is supported by adoption among Pharmaceutical & Biotechnology Companies, and Contract Research Organizations (CROs) and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.
Market Dynamics:
Growing adoption across Gastrointestinal Tumor Model, and Gynecological Tumor Model, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global patient derived xenograft model market. A wider range of available options is making these solutions accessible to a broader base of users.
For instance, companies are expanding their portfolios to address evolving requirements across Pharmaceutical & Biotechnology Companies, and Contract Research Organizations (CROs). Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global patient derived xenograft model market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include THE JACKSON LABORATORY, Champions Oncology, Inc, Charles River Laboratories, Crown Bioscience, Hera Biolabs, Horizon Discovery Ltd., Oncodesign, Pharmatest Services, Shanghai LIDE Biotech, Aragen Life Sciences Ltd., Creative Animodel, Urosphere, and Applied StemCell and WuXi AppTec, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global patient derived xenograft model market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global patient derived xenograft model market.
Detailed Segmentation:
- Global Patient Derived Xenograft Model Market, By Model Type (Revenue, USD Bn, 2021 - 2033)
- Cell line derived models
- Patient derived organoids
- Genetically engineered models and Others (Primary cell derived models, cell processed models etc.)
- Global Patient Derived Xenograft Model Market, By Implantation Method (Revenue, USD Bn, 2021 - 2033)
- Subcutaneous Implantation
- Orthopedic Implantation and Others
- Global Patient Derived Xenograft Model Market, By Tumor Type (Revenue, USD Bn, 2021 - 2033)
- Blood Cancer Models
- Solid Tumor Models
- Pediatric Tumor Models
- Other Rare Tumor Models
- Combination PDX Models
- Custom PDX Models
- Others
- Global Patient Derived Xenograft Model Market, By Application (Revenue, USD Bn, 2021 - 2033)
- Gastrointestinal Tumor Model
- Gynecological Tumor Model
- Respiratory Tumor Model and Other Tumor Model
- Global Patient Derived Xenograft Model Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutions
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- THE JACKSON LABORATORY*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Champions Oncology, Inc
- Charles River Laboratories
- Crown Bioscience
- Hera Biolabs
- Horizon Discovery Ltd.
- Oncodesign
- Pharmatest Services
- Shanghai LIDE Biotech
- Aragen Life Sciences Ltd.
- Creative Animodel
- Urosphere
- Applied StemCell and WuXi AppTec
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Patient Derived Xenograft Model, By Model Type
- Market Patient Derived Xenograft Model, By Implantation Method
- Market Patient Derived Xenograft Model, By Tumor Type
- Market Patient Derived Xenograft Model, By End User
- Market Patient Derived Xenograft Model, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Increasing Cancer Research
- Restraints
- Limitations of PDX Models
- Opportunities
- Applications in Immunotherapy Testing
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Patient Derived Xenograft Model Market , By Model Type, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tumor explant models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Cell line derived models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Patient derived organoids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Genetically engineered models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Others (Primary cell derived models, cell processed models etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
5. Patient Derived Xenograft Model Market , By Implantation Method, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Subcutaneous Implantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Orthopedic Implantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
6. Patient Derived Xenograft Model Market , By Tumor Type, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Gastrointestinal Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Gynecological Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Respiratory Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Other Tumor Model
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
7. Patient Derived Xenograft Model Market , By End User, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Pharmaceutical & Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Contract Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Academic & Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
8. Patient Derived Xenograft Model Market , By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2023and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022-2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- THE JACKSON LABORATORY
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Champions Oncology, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Charles River Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Crown Bioscience
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hera Biolabs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Horizon Discovery Group
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Oncodesign
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pharmatest Services
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Shanghai LIDE Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aragen Life Sciences Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Creative Animodel
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Urosphere
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Applied StemCell
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- WuXi AppTec
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
